Feng Chi Biotech Corp.

As of June 30, 2026, Feng Chi Biotech Corp. carries a market capitalization of 234.08M, placing it among publicly traded companies globally. Its enterprise value stands at 66.27M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of June 30, 2026, Feng Chi Biotech Corp. has 15.40M shares outstanding.

These figures are as of June 30, 2026.

As of June 30, 2026, Feng Chi Biotech Corp. maintains a current ratio of 4.48, meaning it holds 4.5x the short-term assets needed to cover near-term liabilities.

As of the close on October 14, 2026, Feng Chi Biotech Corp.'s stock has declined approximately 25.13% over the past 52 weeks. The 50-day moving average sits at 14.84, while the 200-day moving average is 16.47.

As of June 30, 2026, Feng Chi Biotech Corp. holds 171.85M in cash and equivalents against 4.04M in total debt, resulting in a net debt position of -10.25M. Total book value stands at 229.51M, with working capital of 174.67M providing operational flexibility.